Timetable for Completion. The final work product shall include 10 spiral bound copies of the manuscript delivered to the Trust and two (2) electronic digital copies in CD-ROM diskette format. Final Manuscript shall be formatted consisted with the Author and Editor Guidelines: Manuscript Preparation and Book Production as specified by Rutgers University Press, and can be found: xxxx://xxxxxxxxxxxx.xxxxxxx.xxx/acatalog/Author_Editor_Guidelines.html Research File – one hard copy and (2) electronic digital copies in CD-ROM diskette format Image file containing electronic images suitable for publication of 300 dpi or greater, with accurate accreditation as may be required; and list of potential images suitable for publication where owner permission must be obtained.
Timetable for Completion. The Parties will use, and will direct the Expert to use, commercially reasonable efforts to resolve a dispute within forty-five (45) days after the selection of the Expert or, if resolution within forty-five (45) days is not reasonably achievable, as determined by the Expert, then as soon thereafter as is reasonably practicable.
Timetable for Completion. The Parties will use, and will direct the Expert to use, commercially reasonable efforts to resolve a dispute no later than forty-five (45) days after the selection of the Expert, or if resolution no later than forty-five (45) days is not reasonably achievable, as determined by the Expert, then as soon thereafter as is reasonably practicable. EXHIBIT D Press Release CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes - Aims to develop an immune-evasive stem cell therapy as a potentially curative treatment for diabetes -- Parties will collaborate through commercialization and share costs and profits worldwide - ZUG, Switzerland and CAMBRIDGE, Mass., and SAN DIEGO, September 17, 2018 -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a privately held regenerative medicine company, today announced a collaboration focused on the discovery, development, and commercialization of gene-edited allogeneic stem cell therapies for the treatment of diabetes. Decades of clinical data with islet transplants indicate that beta-cell replacement approaches may offer curative benefit to patients with insulin-requiring diabetes. ViaCyte has pioneered the approach of generating pancreatic-lineage cells from stem cells and delivering them safely and efficiently to patients. PEC-Direct, ViaCyte’s lead product candidate currently being evaluated in the clinic, uses a non-immunoprotective delivery device that permits direct vascularization of the cell therapy. This approach has the potential to deliver durable benefit; however, because the patient’s immune system will identify these cells as foreign, PEC-Direct will require long-term immunosuppression to avoid rejection. As a result, PEC-Direct is being developed as a therapy for the subset of patients with type 1 diabetes at high risk for acute complications. CRISPR gene editing offers the potential to protect the transplanted cells from the patient’s immune system by ex-vivo editing immune-modulatory genes within the stem cell line used to produce the pancreatic-lineage cells. The speed, specificity, and multiplexing efficiency of the CRISPR system make it ideally suited to this task. CRISPR Therapeutics is pursuing a similar approach for its allogeneic CAR-T programs and has established significant expertise in immune-evasive gene editing. T...
Timetable for Completion. Unless otherwise agreed to by the Parties in writing, in any arbitration under this Section 13.9, the Parties and the arbitrator will use all reasonable efforts to resolve such Dispute within sixty (60) days following the selection of the arbitrator, or as soon thereafter as is reasonably practicable.
Timetable for Completion. Avecia shall use all Commercially Reasonable Efforts to successfully complete the initial process validation of the M1 Facility as soon as possible but no later than (*). If such initial process validation of the M1 Facility is not successfully completed by (*). Such successful completion shall include, without limitation, approval by the Genta quality assurance audit team of Avecia's technical reports submitted in connection with such process validation and three successful consecutive validation Batches of API. Avecia shall conduct validation activities as needed anytime thereafter during the term of this Agreement, in consultation with Genta. Avecia shall routinely prepare, assemble and retain any reports, documents and validation summary reports pertaining to the Manufacturing Facilities and manufacturing and processing activities hereunder in accordance with Section 10.2 and that are required for the validation and qualification process. Avecia shall provide copies of such required documents and reports to Genta for approval thereof as part of the validation and qualification process.
Timetable for Completion iXL will provide interactive services on the ------------------------ timetable established in the "Project Timetable and Deliverables Schedule" in the Statement of Work (the "Project Timetable"). Endeavor will provide to iXL the media elements, materials, timely approvals, and assistance necessary for iXL to complete the Custom Works and other services on the Project Timetable. Any delay by Endeavor in providing materials, approvals, and assistance to iXL shall extend the deadline for the subsequent tasks of iXL under the Project Timetable by a period at least equal to Endeavor's delay. In addition, for any Endeavor obligation described as time-sensitive or critical in the Statement of Work, failure of Endeavor to meet its deadline will entitle iXL to prepare a revised Project Timetable based on a realistic estimate of the effect of the delay on the completion of the project, taking into account other work scheduled by iXL. In addition to providing progress reports and arranging project planning meetings to the extent required under the Project Timetable, iXL agrees that the current prototype of the Custom Works shall be accessible to Endeavor throughout the development phase at the URL identified in the Statement of Work.
Timetable for Completion iXL will provide the services and products to prepare and complete the Client Web Site on the timetable established in the "Project Timetable, Works Delivery and Payment Schedule" in the Statement (the "Project Timetable"). Client will provide to iXL the Client Materials including all media elements, materials, timely approvals, and assistance necessary for iXL to complete the Client Web Site on the Project Timetable. Any delay by the Client in providing materials, approvals, and assistance to iXL shall extend the deadline for the subsequent tasks of iXL under the Project Timetable by a period at least equal to Client's delay. In addition, for any Client obligation described as time-sensitive or critical in the Statement, failure of the Client to meet its deadline will entitle iXL to prepare a revised Project Timetable based on a realistic estimate of the effect of the delay on the completion of the project, taking into account other work scheduled by iXL.
Timetable for Completion. The Parties shall use, and shall direct the Expert Committee to use, diligent efforts to resolve any Expert Committee Dispute within [***] after the selection of the third Expert, or if resolution within [***] days is not reasonably achievable, as determined by the Expert Committee, then as soon thereafter as is reasonably practicable.
Timetable for Completion. The Parties shall use, and shall direct the Expert to use, best efforts to resolve any Expert Dispute within [* * *] after the selection of the Expert, or if resolution within [* * *] is not reasonably achievable, as determined by the Expert, then as soon thereafter as is reasonably practicable.
